Results 61 to 70 of about 4,306 (252)

Fluocinolone Acetonide Ophthalmic ??? Bausch & Lomb

Drugs in R & D, 2005
Bausch & Lomb and Control Delivery Systems have developed an intravitreal implant that can deliver the corticosteroid fluocinolone acetonide [fluocinolone acetonide implant, Retisert] to posterior eye tissue for up to 3 years. The implant uses Bausch & Lomb's Envision TD technology.
openaire   +2 more sources

The determination of fluocinolone acetonide in formulated products

Journal of Pharmacy and Pharmacology, 1966
Abstract A chromatographic procedure for the determination of fluocinolone acetonide is described. The method employs a hexane: dioxan: water partition system supported on Celite. The progress of the chromatogram is followed by measurement of the ultraviolet absorption of eluate fractions at 238 mμ.
A. Holbrook, F. Bailey, R. J. Miller
openaire   +2 more sources

Neuroichthyosis With a De Novo Variant c.494C>T in ELOVL1 and Severe Pruritus Relieved by Dupilumab

Pediatric Dermatology, EarlyView.
ABSTRACT We report a patient with neuroichthyosis with an ELOVL1 variant associated with severe pruritus who responded well to dupilumab therapy. Our case is the third known patient reported with this de novo heterozygous dominant variant. The feature of severe progressive pruritus greatly impairing quality of life is unique among these reports.
Danielle Marcoux, Sophie‐Anne Savard, Victor Kokta, Elsa Rossignol, Luis H. Ospina   +4 more
wiley   +1 more source

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T., Bonfiglio V., Fallico M., Fichera S., Longo A., Macchi I., Pizzo A., Rapisarda C., Reibaldi M., Russo A.   +9 more
core   +2 more sources

Development and characterization of pluronic lecithin organogel containing fluocinolone acetonide

Drug Development and Industrial Pharmacy, 2021
The rabble-rousing skin condition can be conventionally treated, but due to some demerits, there is a need to find a novel approach with an appropriate release profile. The research work narrates the optimization of the topical delivery system of Fluocinolone acetonide loaded in pluronic lecithin organogel. The preliminary studies were carried out and,
Dinal Patel, Viral Patel
openaire   +4 more sources

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

Cancer Innovation, Volume 4, Issue 3, June 2025.
ABSTRACT Background The phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced breast cancer.
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, The Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association, The Society of Onco‐Pathology of the China Anti‐Cancer Association   +3 more
wiley   +1 more source

Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives

Experimental Dermatology, Volume 34, Issue 4, April 2025.
ABSTRACT JAK inhibitors are used to treat various inflammatory skin diseases. However, systemic formulations are associated with an increased risk of major adverse events. Ruxolitinib 1.5% cream is a selective topical JAK1 and JAK2 inhibitor, which has recently been approved by EMA and MHRA for treating non‐segmental vitiligo, while being FDA‐approved ...
Marco Spadafora, Serena Morsia, Vito Giuseppe Di Lernia, Shaniko Kaleci, Giovanni Pellacani, Caterina Longo   +5 more
wiley   +1 more source

Treatment of Solar Lentigines: A Systematic Review of Clinical Trials

Journal of Cosmetic Dermatology, Volume 24, Issue 4, April 2025.
ABSTRACT Background Solar lentigines, resulting from chronic UV exposure, are early signs of photoaging and can significantly affect individuals. Aims This systematic review evaluates the efficacy, safety, and tolerability of treatments for solar lentigines in light of a lack of conclusive evidence regarding optimal therapy options.
Ghazal Mardani, Mohammad Javad Nasiri, Nastaran Namazi, Mehdi Farshchian, Fahimeh Abdollahimajd   +4 more
wiley   +1 more source

Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema

Clinical Ophthalmology, 2013
Christos Haritoglou, Aljoscha S Neubauer, Marcus KerntDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyAbstract: Diabetic macular edema (DME) is a potentially sight-threatening disease that predominantly affects patients with ...
Haritoglou C, Neubauer AS, Kernt M
doaj  

Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema [PDF]

, 2023
Diabetic macular edema (DME) is a common sight-threatening complication of diabetic retinopathy (DR) and the leading cause of severe visual impairment among the working-age population.
Buffon G, Coco G, Giannaccare G., Rastelli D, Scorcia V, Taloni A   +5 more
core   +1 more source